Freshfields is advising SERB Pharmaceuticals on its agreement to acquire Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on novel, radioimmunotherapy and antibody-based therapeutic cancer products. Read more details of this transaction here.

The Freshfields Team was led by corporate/M&A partners Paul Humphreys and Sebastian Fain and Life Sciences partner Jeff Jay. The corporate/M&A team included associates Wicy Wang, Sahara Baker, Arash Ardalan and Simon Trisk, as well as Life Sciences team members, Ben Cohen, Dr. Zackory Burns, Juliana Zhang and Wolfgang Paulson.

Additional team members included:

• Executive Compensation/Employee Benefits: Lori Goodman, Jordan Salzman, Jordan Riley
• Finance: Aled Batey, Richard Daniels, Christina Banz and Kelsey Pepper
• Capital Markets: Michael Levitt
• Sanctions: Stephanie Brown Cripps, Young Park
• Data Privacy: Christine Chong

SERB Pharmaceuticals is a portfolio company of Charterhouse Capital Partners.